417 related articles for article (PubMed ID: 19065993)
1. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
4. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
5. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
6. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
7. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 inhibitors in clinical practice.
Palalau AI; Tahrani AA; Piya MK; Barnett AH
Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK; Lereun C; Wright D
Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
12. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
13. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
15. New treatments for diabetes.
Bloomgarden ZT; Inzucchi SE
N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
[No Abstract] [Full Text] [Related]
16. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
[No Abstract] [Full Text] [Related]
17. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
18. [New concepts in the treatment of type 2 diabetes].
Meier JJ; Schmidt WE; Klein HH
Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
20. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Ahrén B
Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]